Cepi

Two of Tennessee's Retirement Specialists, Greg McGee and Ryan Moore, Co-Author New Book to Help Retirees Avoid Retirement Mistakes and Cut Taxes

Retrieved on: 
Wednesday, May 18, 2022
Certification, Sport, Cepi, Leadership, Gold, Parent, Solution, Cirrus, Cirrus SR22, Failure, McGee, Thought, Industry, Retirement, CEP, Grandparent, Pension, CFF, Face, Founder, Mistake, CEO, Book, Financial adviser

The new book educates and equips retirees against the little-known mistakes and costly missteps that can derail their lifestyle in retirement.

Key Points: 
  • The new book educates and equips retirees against the little-known mistakes and costly missteps that can derail their lifestyle in retirement.
  • "It wasn't so long ago that retirement meant peace of mind with a pension and a gold watch for our parents and grandparents.
  • Keeping it is another," shares Ryan Moore, CFF, CEP, financial educator, author, speaker and CEO of Retirement Solutions Group.
  • Greg McGee continues, "As a result of widely held myths about money and retirement, many are making some costly mistakes.

H.B. Fuller Joins 4evergreen Alliance

Retrieved on: 
Thursday, March 3, 2022
Packaging, Chemicals, Plastics, Environment, Manufacturing, Adhesive, Alliance, Cepi, Beauty, H.B. Fuller, Certification, Organization, Into the Woods, Staab, Confederation of European Paper Industries, Awareness, NYSE, Recycling, Fast-moving consumer goods, PEFC, Program, CPG, Electronics, Health, Transport, Carbon, Renewable energy

Fuller Company (NYSE: FUL), a leading global adhesives provider, announced that they have recently joined the 4evergreen alliance, a cross-industry alliance hosted by the Confederation of European Paper Industries (Cepi) to improve the circularity of fiber-based packaging.

Key Points: 
  • Fuller Company (NYSE: FUL), a leading global adhesives provider, announced that they have recently joined the 4evergreen alliance, a cross-industry alliance hosted by the Confederation of European Paper Industries (Cepi) to improve the circularity of fiber-based packaging.
  • The goal of the alliance is to raise the overall recycling rate of fiber-based packaging to 90% by 2030 and contribute to a climate neutral and sustainable society.
  • Fuller Global Sustainability Manager Elizabeth Staab says, This is both an exciting and challenging period for the packaging industry.
  • Fuller, and we are joining the 4evergreen Alliance to expand collaboration with a variety of companies.

Benevity Partners with the “Go Give One” Campaign to Address Global COVID-19 Vaccine Inequity

Retrieved on: 
Thursday, August 5, 2021
ACT, World Health Organization, Chief executive officer, Solution, Vaccine, COVID-19, AMC, COVAX, Cepi, Coalition, Lead, Act, Partnership, Software, Coalition for Epidemic Preparedness Innovations, Vaccination, GAVI, World, Workforce, Private sector, UNICEF, Gavi, Access, Epidemic, Movement, PagerDuty, Accelerator, GLOBE, Pharmaceutical industry

This partnership adds to the support Benevitys platform has been driving towards access to vaccines and COVID relief efforts.

Key Points: 
  • This partnership adds to the support Benevitys platform has been driving towards access to vaccines and COVID relief efforts.
  • With Benevitys platform, we were able to quickly launch our employee match campaign, activate and amplify our peoples efforts.
  • If 2020 taught us anything, its that our global community doesnt experience crisis equally, said Kelly Schmitt, CEO of Benevity.
  • For more information on One World Protected, the fundraising campaign of the Gavi COVAX AMC, click here .

Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate

Retrieved on: 
Thursday, August 5, 2021
Company, Infection, Headache, Vaccine, Cepi, Food and Drug Administration Amendments Act of 2007, Population, Alphavirus, Seroconversion, European, Coalition, VLA, Data monitoring committee, Fever, Human, Priority review, Mortality, Coalition for Epidemic Preparedness Innovations, Developing country, Aedes, European Medicines Agency, Program, COVID-19, Fatigue, Myalgia, Safety, EMA, MD, Nausea, Antibody, Food and Drug Administration, Disease, Rash, Profile, Epidemic, Euronext Paris, Nasdaq, Immunization, Lyme disease, PRV, Breakthrough therapy, Marketing, Licensure, Ageing, Genome, Food, Travel, Pharmaceutical industry

The vaccine candidate was highly immunogenic with a GMT of approximately 3,270, confirming the immunogenicity profile seen in the Phase 1 trial.

Key Points: 
  • The vaccine candidate was highly immunogenic with a GMT of approximately 3,270, confirming the immunogenicity profile seen in the Phase 1 trial.
  • Juan Carlos Jaramillo, M.D, Chief Medical Officer of Valneva commented, We are delighted with these Phase 3 results confirming the compelling profile of our vaccine candidate across all age groups.
  • These first-ever Phase 3 trial results for a chikungunya vaccine mean that we are a step closer to addressing this major, growing and unmet public health threat.
  • VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus, which has spread to more than 100 countries.

Hatch raises C$1 million for COVAX and UNICEF

Retrieved on: 
Wednesday, July 7, 2021
Organizations, Articles, Medicine, World Health Organization, UNICEF, COVAX, Medical research, Coalition for Epidemic Preparedness Innovations, Cepi, UNICEF Canada, Gavi, COVID-19 vaccine

Through the employees generous donations and a corporate match,$C1 million was raised!

Key Points: 
  • Through the employees generous donations and a corporate match,$C1 million was raised!
  • COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization, alongside key delivery partner, UNICEF.
  • On behalf of UNICEF, I would like to thank Hatch foritssupport in ensuring widespread and equitable delivery of COVID-19 vaccines.Theystepped up to help UNICEFin its efforts todeliver the largest fastest immunizationcampaignin history.
  • We are grateful to Hatch employees fortheircontributions and to Hatch for increasing the impact by matching every dollar raised,shared David Morley, UNICEF Canadas President and CEO.

LumaCyte Appoints Vaccine Manufacturing Expert to Scientific Advisory Board

Retrieved on: 
Tuesday, April 20, 2021
Manufacturing, Health, General Health, Healthcare reform, Other Science, Research, Other Manufacturing, Infectious diseases, Public policy, Government, Science, Chemicals, Plastics, Medical specialties, Health care, Companies, Sanofi, Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Epidemics, Wellcome Trust, Novavax, Sanofi Pasteur, Vaccine, Cepi

b"LumaCyte , a leader in advanced label-free single-cell analytics through its novel Laser Force Cytology\xe2\x84\xa2 (LFC\xe2\x84\xa2) platform, announces today the addition of Jim Robinson to its Scientific Advisory Board (SAB).

Key Points: 
  • b"LumaCyte , a leader in advanced label-free single-cell analytics through its novel Laser Force Cytology\xe2\x84\xa2 (LFC\xe2\x84\xa2) platform, announces today the addition of Jim Robinson to its Scientific Advisory Board (SAB).
  • Jim brings more than 35 years of CMC vaccine manufacturing experience to the LumaCyte SAB, holding previous executive level positions at Merck, Sanofi Pasteur and Novavax, and is currently a member and the Vice Chair of the Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee.
  • Jim will join Gray Heppner , MD, FACP, FASTMH, who is the Chief Medical Officer at VAXXINITY and has been a member of the LumaCyte SAB since 2017.
  • Rapid optimization of both upstream and downstream manufacturing processes is key to getting vaccines to patients much faster than ever before.

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

Retrieved on: 
Monday, February 1, 2021
Medical research, Medicine, Health sciences, Medical specialties, Cepi, Cepi, Vaccination, COVID-19 vaccine, Vaccine, Coalition for Epidemic Preparedness Innovations

"CEPI has been instrumental in supporting vaccine development to address the COVID-19 pandemic," commented Ryan Spencer , Chief Executive Officer of Dynavax.

Key Points: 
  • "CEPI has been instrumental in supporting vaccine development to address the COVID-19 pandemic," commented Ryan Spencer , Chief Executive Officer of Dynavax.
  • This stockpile of CpG 1018 will be first available for purchase by CEPI grantees for use in approved COVID-19 vaccines.
  • Dynavax will sell the reserved CpG 1018 under separate commercial supply agreements made directly with CEPI grantees within price parameters agreed with CEPI.
  • Upon sale of CpG 1018 manufactured under this agreement, Dynavax will reimburse CEPI for the funded manufacturing cost.

Novavax Announces Facility Expansion to Support Global Vaccine Development

Retrieved on: 
Monday, November 2, 2020
Medical specialties, Medicine, Health care, Novavax, Medical research, Coalition for Epidemic Preparedness Innovations, COVID-19 vaccine, Cepi, Cepi, Vaccine, Influenza vaccine, Draft:Biotechnology stocks in the COVID-19 pandemic

Novavax has secured two additional properties in Gaithersburg, Maryland to support the Companys immediate need for additional laboratory and office space for manufacturing, R&D and business operations.

Key Points: 
  • Novavax has secured two additional properties in Gaithersburg, Maryland to support the Companys immediate need for additional laboratory and office space for manufacturing, R&D and business operations.
  • Novavax has also created a global production network to enable manufacturing and rapid distribution across the U.S., Asia and Europe if and when its COVID-19 vaccine is approved for use.
  • The expansion of our physical footprint reflects Novavax significant growth as we work to both rapidly deliver a COVID-19 vaccine and progress NanoFlu, our influenza vaccine candidate, for regulatory submission and potential commercialization, said Stanley C. Erck, President and CEO, Novavax.
  • Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

Gov. Hogan, Novavax’ Erck, & BIO’s Dr. McMurry-Heath Toured Novavax Labs and Discussed Progress on COVID-19 Vaccine

Retrieved on: 
Thursday, September 24, 2020
Health, Medicine, Vaccination, Vaccines, Medical research, COVID-19 vaccine, Novavax, Influenza vaccines, Coalition for Epidemic Preparedness Innovations, Vaccine, Cepi, Cepi

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

Key Points: 
  • BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
  • NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
  • NVXCoV2373 is a vaccine candidate engineered from the genetic sequence of SARSCoV2, the virus that causes COVID-19 disease.
  • Novavaxhas secured$2 billionin funding for its global coronavirus vaccine program, including up to$388 millionin funding from theCoalition for Epidemic Preparedness Innovations(CEPI).